Jan 31, 2025 · Axsome is developing innovative treatments including AXS-05, AXS-12, and AXS‑14. learn about our pipeline Axsome focuses on CNS conditions including depression, Alzheimer's disease agitation, migraine, narcolepsy and fibromyalgia.

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions.

leave axsome.com. You will now be sent to a website that is not controlled or owned by Axsome Therapeutics, Inc. Axsome Therapeutics, Inc. is not responsible or liable for the website you are about to go to, which may not be appropriate for everyone.

Get information on Axsome products that are currently in-market, developed to find new ways to solve treatment gaps in CNS conditions.

View a list of current career opportunities at Axsome Therapeutics and submit an application.

AXS-05 (dextromethorphan-bupropion) is a novel, oral, NMDA receptor antagonist being developed for the treatment of multiple CNS conditions. Learn more and see clinical and regulatory information.

Axsome Therapeutics is a biopharmaceutical company committed to developing therapies that transform patients’ lives. We’re creative, entrepreneurial, and growing! Interested in joining us? Take a look at the opportunities we’ve got available.

Learn more about the conditions we focus on and the work Axsome is doing to bring meaningful changes for patients with CNS conditions.

See how you can contact Axsome Therapeutics by phone, email, or standard mail or submit a contact request.

Mr. Maizel has served as our Chief Commercial Officer since October 2024 and has been a member of the Axsome team since October 2023. Prior to joining Axsome, Mr. Maizel was the Vice President, US Psychiatry at AbbVie where he oversaw sales and marketing for …